SRDX vs. ANGO, OFIX, ARAY, CTSO, ATRC, NPCE, BVS, CVRX, RCEL, and ANIK
Should you be buying Surmodics stock or one of its competitors? The main competitors of Surmodics include AngioDynamics (ANGO), Orthofix Medical (OFIX), Accuray (ARAY), Cytosorbents (CTSO), AtriCure (ATRC), NeuroPace (NPCE), Bioventus (BVS), CVRx (CVRX), AVITA Medical (RCEL), and Anika Therapeutics (ANIK). These companies are all part of the "surgical & medical instruments" industry.
Surmodics (NASDAQ:SRDX) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.
Surmodics has higher earnings, but lower revenue than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.
Surmodics presently has a consensus price target of $59.00, suggesting a potential upside of 123.32%. AngioDynamics has a consensus price target of $14.25, suggesting a potential upside of 125.83%. Given AngioDynamics' higher possible upside, analysts clearly believe AngioDynamics is more favorable than Surmodics.
96.6% of Surmodics shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 8.9% of Surmodics shares are owned by company insiders. Comparatively, 5.1% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Surmodics had 11 more articles in the media than AngioDynamics. MarketBeat recorded 16 mentions for Surmodics and 5 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 1.27 beat Surmodics' score of 0.74 indicating that AngioDynamics is being referred to more favorably in the news media.
Surmodics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.
Surmodics has a net margin of 3.99% compared to AngioDynamics' net margin of -60.21%. Surmodics' return on equity of 8.06% beat AngioDynamics' return on equity.
AngioDynamics received 28 more outperform votes than Surmodics when rated by MarketBeat users. However, 66.87% of users gave Surmodics an outperform vote while only 60.67% of users gave AngioDynamics an outperform vote.
Summary
Surmodics beats AngioDynamics on 12 of the 17 factors compared between the two stocks.
Get Surmodics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Surmodics Competitors List
Related Companies and Tools
